<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086369</url>
  </required_header>
  <id_info>
    <org_study_id>15844</org_study_id>
    <secondary_id>I5B-MC-JGDP</secondary_id>
    <secondary_id>2016-001099-31</secondary_id>
    <nct_id>NCT03086369</nct_id>
  </id_info>
  <brief_title>A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and
      gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs) Phase 1b</measure>
    <time_frame>Cycle 1 (28 Days)</time_frame>
    <description>Number of participants with DLTs phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) Phase 2</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Approximately 9 Months)</time_frame>
    <description>OS phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Olaratumab</measure>
    <time_frame>Baseline through End of Study (Approximately 9 Months)</time_frame>
    <description>PK: Cmin of olaratumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Olaratumab Antibodies</measure>
    <time_frame>Baseline through End of Study (Approximately 9 Months)</time_frame>
    <description>Number of participants with anti-olaratumab antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Phase 1b</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Approximately 9 Months)</time_frame>
    <description>OS phase 1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline to Disease Progression or Death (Approximately 6 Months)</time_frame>
    <description>PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline through Disease Progression or Death (Approximately 6 Months)</time_frame>
    <description>ORR: Percentage of participants who achieve CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 5.5 Months)</time_frame>
    <description>DoR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Worsening of the Brief Pain Inventory Short Form Modified (mBPI-sf) &quot;Worst Pain Score&quot;</measure>
    <time_frame>Baseline through Follow-up (Approximately 9 Months)</time_frame>
    <description>Time to first worsening of the mBPI-sf &quot;worst pain score&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Worsening of Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Scale Scores</measure>
    <time_frame>Baseline through Follow-up (Approximately 9 Months)</time_frame>
    <description>Time to sustained worsening of symptom burden on the EORTC QLQ-C30 scale scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status on the EuroQol 5-Dimension 5 Level (EQ-5D-5L)</measure>
    <time_frame>Baseline through Follow-up (Approximately 9 Months)</time_frame>
    <description>Health status on the EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Double Blind) Olaratumab, nab-paclitaxel and gemcitabine given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Double Blind) Placebo, nab-paclitaxel and gemcitabine given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaratumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <other_name>LY3012207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)</arm_group_label>
    <arm_group_label>Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)</arm_group_label>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo + Nab-paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that
             is metastatic (Stage IV) and not amenable to resection with curative intent.

          -  If present, clinically significant or symptomatic amounts of ascites should be drained
             prior to Day 1.

          -  Have had no prior systemic treatment for metastatic disease. Prior adjuvant or
             neo-adjuvant chemotherapy or radiochemotherapy (other than nab-paclitaxel) is allowed
             if completed ≥3 months prior to enrollment and no lingering toxicities are present.

          -  Prior radiation therapy for treatment of cancer is allowed to &lt;25% of the bone marrow.

          -  Phase 2: archival tumor tissue or be willing to provide a pre-treatment biopsy.

          -  Measurable or nonmeasurable but evaluable disease as defined by the Response
             Evaluation Criteria in Solid Tumors (RECIST 1.1).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

          -  Discontinued all previous treatments for cancer ≥4 weeks prior.

          -  Adequate organ function.

          -  Life expectancy of at least 3 months.

        Exclusion Criteria:

          -  Serious concomitant systemic disorder.

          -  Have received first line treatment for metastatic pancreatic cancer.

          -  Received prior treatment with nab-paclitaxel.

          -  Have known central nervous system malignancy or metastasis.

          -  Current hematologic malignancies.

          -  Participated within the last 30 days in a clinical trial involving an investigational
             product.

          -  Women with a positive pregnancy test or lactating.

          -  Have endocrine pancreatic tumors or ampullary cancer.

          -  Currently enrolled in another clinical trial.

          -  Have a known additional malignancy that is progressing or required active treatment
             within the past 1 year.

          -  Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug
             formulations.

          -  Are taking certain anti-coagulant medications such as warfarin and are unable to be
             switched to other similar medicines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TGen Clinical Research Services at Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Jude Medical Center</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRIO - Translational Research in Oncology-US, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Santa Barbara with Sansum Clinic</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists and Research Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>63142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Research/USD</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison Hospital and Health Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-4108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/pancreatic-cancer/JGDP#?postal=</url>
    <description>A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Olaratumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

